Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jason J Luke

Showing results (21-30 of 185) with videos related to

Pageof 19
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 3, 2023
CD4+ TIL to the Rescue of Anti-PD-1 Failure by Targeting MHC-IIAllison Betof Warner, Jason J Luke
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 3, 2021
Ipilimumab Combination Dosing: Less is MoreMax Jameson-Lee, Jason J Luke
Clinics in Dermatology|April 24, 2013
Chemotherapy in the management of advanced cutaneous malignant melanomaJason J Luke, Gary K Schwartz
American Journal of Clinical Dermatology|February 27, 2024
Rapidly Evolving Pre- and Post-surgical Systemic Treatment of MelanomaRyan C Augustin, Jason J Luke
NEJM Evidence|February 6, 2024
Progression/Recurrence-Free Survival 2 in Adjuvant MelanomaRyan C Augustin, Jason J Luke
Current Oncology Reports|May 24, 2024
Beyond Immune Checkpoint Inhibitors: Emerging Targets in Melanoma TherapyAndrew D Knight, Jason J Luke
Current Oncology Reports|August 3, 2021
Next-Generation Immunotherapy Approaches in MelanomaTyler Buchanan, Afsaneh Amouzegar, Jason J Luke
Genome Medicine|October 27, 2020
Molecular correlates and therapeutic targets in T cell-inflamed versus non-T cell-inflamed tumors across cancer typesRiyue Bao, Daniel Stapor, Jason J Luke
Oncotargets and Therapy|October 29, 2020
Toll-Like Receptor 9 Agonists in CancerLilit Karapetyan, Jason J Luke, Diwakar Davar
Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy|January 4, 2019
The Impact of the Fecal Microbiome on Cancer ImmunotherapyAfaf E G Osman, Jason J Luke
Pageof 19

Showing results (21-30 of 185) with videos related to

Sort By:
Pageof 19
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 3, 2023
CD4+ TIL to the Rescue of Anti-PD-1 Failure by Targeting MHC-IIAllison Betof Warner, Jason J Luke
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 3, 2021
Ipilimumab Combination Dosing: Less is MoreMax Jameson-Lee, Jason J Luke
Clinics in Dermatology|April 24, 2013
Chemotherapy in the management of advanced cutaneous malignant melanomaJason J Luke, Gary K Schwartz
American Journal of Clinical Dermatology|February 27, 2024
Rapidly Evolving Pre- and Post-surgical Systemic Treatment of MelanomaRyan C Augustin, Jason J Luke
NEJM Evidence|February 6, 2024
Progression/Recurrence-Free Survival 2 in Adjuvant MelanomaRyan C Augustin, Jason J Luke
Current Oncology Reports|May 24, 2024
Beyond Immune Checkpoint Inhibitors: Emerging Targets in Melanoma TherapyAndrew D Knight, Jason J Luke
Current Oncology Reports|August 3, 2021
Next-Generation Immunotherapy Approaches in MelanomaTyler Buchanan, Afsaneh Amouzegar, Jason J Luke
Genome Medicine|October 27, 2020
Molecular correlates and therapeutic targets in T cell-inflamed versus non-T cell-inflamed tumors across cancer typesRiyue Bao, Daniel Stapor, Jason J Luke
Oncotargets and Therapy|October 29, 2020
Toll-Like Receptor 9 Agonists in CancerLilit Karapetyan, Jason J Luke, Diwakar Davar
Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy|January 4, 2019
The Impact of the Fecal Microbiome on Cancer ImmunotherapyAfaf E G Osman, Jason J Luke
Pageof 19